Drug name(s)
Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq Tregzi™Indications and usage
Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq is indicated for use in matched donor hematopoietic stem cell transplantation with myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGVHD)-free survival, in the treatment of adults with hematological malignancies.
Side effects needing medical attention
The most common adverse reactions were mucositis, diarrhea, rash, viral infections, infections-pathogen unspecified, abdominal pain, vomiting, nausea, bacterial infections, hemorrhage, acute GVHD, edema, and fungal infections.
The most common lab abnormalities were lymphocyte count decreased, platelet count decreased, leukocyte count decreased, neutrophil count decreased, and hemoglobin decreased.